

PRESS CLIPPING SHEET

PUBLICATION:	Egyptian Gazette
DATE:	04-June-2017
COUNTRY:	Egypt
CIRCULATION:	60,000
TITLE :	New treatment for growth hormone deficiency
PAGE:	05
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Amina Abdel Salam
AVE:	11,500

New treatment for growth hormone deficiency

A MAJOR pharmaceutical company operating in Egypt has recently launched a biopharmaceutical medicine to treat growth hormone deficiency patients approved by the US Food and Drug Administration (FDA) and European Medicine Agency (EMA).

Dr Mona Salem, Professor of Paediatric Endocrinology and Diabetes at Ain Shams University, explained: "A growth hormone deficiency (GHD) occurs when the pituitary gland fails to produce enough growth hormone. It more commonly affects children than adults, occurring in roughly 1 in 7,000 births."

Thodoris Dimopoulos, the pharmaceutical company's country head for Egypt and Libya, stated: the global leader in biosimilars, has seven decades of experience in biotechnologies using state-of-the-art technologies and facilities.

"The launch of our first biologic drug in Egypt is not only a milestone for the company, but more importantly it paves the way for redefining



FROM left to right: Thodoris Dimopoulos, Dr Mona Salem and Dr Sherine Abdel Ghaffar during the announcement of a new drug to treatment growth hormone deficiency.

patients' access to treatment by offering a high-quality, more affordable version of this important medicine," he added.

Dr Sherine Abdel Ghaffar, Professor of Paediatric Endocrinology and Diabetes at Cairo University, said: "Growth hormone

deficiency is treatable. Children who are diagnosed early often recover very well. Children with congenital GHD are often treated with growth hormone until they reach puberty. However, some remain in treatment for their entire lives.

"Patients treated with growth hor-

mone therapy require an injection of recombinant HGH (somatropin) on a daily basis, which requires significant commitment from the individual, parents or primary caregiver. Pharmaceutical companies understand the importance of providing comprehensive patient support services, and use devices specially designed to offer enhanced simplicity and security during treatment by providing high dose accuracy and safety of use to ensure patients receive the right dose at the right time so they can reach the catch up growth as per treatment guidelines."

Dimopoulos stated that: "The company maintains its commitment to bringing high-quality biologic medicines to patients and healthcare professionals around the world. The purpose is to discover new ways to improve people's lives, by pioneering novel approaches to help people around the world access high-quality medicine and contributing to improve society's ability to support growing healthcare needs."